Sex differences in HIV-1-mediated immunopathology

Current Opinion in HIV and AIDS

Volumn 11, Issue 2, 2016, Pages 209-215

  Ziegler, Susanne ^a   Altfeld, Marcus ^a,b  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HIV; immune activation; interferon ; sex; Toll like receptor 7

Indexed keywords

ALPHA INTERFERON; TOLL LIKE RECEPTOR 7; ESTROGEN; TOLL LIKE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOLOGY; INNATE IMMUNITY; PLASMACYTOID DENDRITIC CELL; PRIMARY INFECTION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; VIRUS LOAD; X CHROMOSOME; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY;

ESTROGENS; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; SEX FACTORS; TOLL-LIKE RECEPTORS;

EID: 84957645561     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000237     Document Type: Review

References (74)

1. Van Lunzen J, Altfeld M. Sex differences in infectious diseases-common but neglected. J Infect Dis 2014; 209 (Suppl 3): S79-S80.
2. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol 2014; 35: 347-369.
3. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis 2014; 209 (Suppl 3): S100-S106.
4. Gabriel G, Arck PC. Sex, immunity and influenza. J Infect Dis 2014; 209 (Suppl 3): S93-S99.
5. Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: does sex play a role? J Infect Dis 2014; 209 (Suppl 3): S81-S85.
6. Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 2014; 209 (Suppl 3): S86-S92.
7. Klein SL. Sex differences in prophylaxis and therapeutic treatments for viral diseases. Handb Exp Pharmacol 2012; 499-522.
8. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 2012; 34: 1050-1059.
9. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptormediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15: 955-959.
10. Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMVspecific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65: 476-485.
11. Hewagama A, Patel D, Yarlagadda S, et al. Stronger inflammatory/cytotoxic T cell response in women identified by microarray analysis. Genes Immun 2009; 10: 509-516.
12. Yurkovetskiy L, Burrows M, Khan AA, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity 2013; 39: 400-412.
13. Seillet C, Laffont S, Tremollieres F, et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 2012; 119: 454-464.
14. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 2010; 10: 594-604.
15. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8: 737-744.
16. Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol 2014; 35: 97-104.
17. LockshinMD. Nonhormonal explanations for sex discrepancy in human illness. Ann N Y Acad Sci 2010; 1193: 22-24.
18. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312: 1669-1672.
19. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002; 296: 1642-1644.
20. Moore AL, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001; 26: 159-163.
21. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
22. World Health Organization 2014 -Department of Maternal, Newborn, Child and Adolescent Health. Health for the World's Adolescents -A Second Chance in The Second Decade. 2014; WHO/FWC/MCA/14.05.
23. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352: 1510-1514.
24. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344: 720-725.
25. Meditz AL, MaWhinney S, Allshouse A, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011; 203: 442-451.
26. Grinsztejn B, Smeaton L, Barnett R, et al. Sex-associated differences in preantiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4+ T cell count. Antivir Ther 2011; 16: 1057-1062.
27. Loupa CV, Rodriguez B, McComsey G, et al. Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. Clin Microbiol Infect 2006; 12: 389-391.
28. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 32 2003; 452-461.
29. Collazos J. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007; 9: 237-245.
30. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19: 577-583.
31. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13: 2361-2364.
32. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-482.
33. Greenblatt RM, Ameli N, Grant RM, et al. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 2000; 181: 82-90.
34. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996; 72: 27-31.
35. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-255.
36. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5: 83-89.
37. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
38. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753-777; table of contents.
39. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
40. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007; 81: 8838-8842.
41. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888.
42. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133.
43. Hardy GA, Sieg S, Rodriguez B, et al. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 2013; 8: e56527.
44. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-447.
45. Lichtenstein B, Malow R. A critical review of HIV-related interventions for women prisoners in the United States. J Assoc Nurses AIDS Care 2010; 21: 380-394.
46. Ren W, Ma Y, Yang L, et al. Fast disease progression in simian HIV-infected female macaque is accompanied by a robust local inflammatory innate immune and microbial response. AIDS 2015; 29: F1-F8.
47. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-666.
48. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199: 1177-1185.
49. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-230.
50. Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immunol 2015; 16: 554-562.
51. Jakobsen MR, Bak RO, Andersen A, et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci USA 2013; 110: E4571-E4580.
52. Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013; 339: 826-830.
53. Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339: 786-791.
54. Blasius AL, Beutler B. Intracellular Toll-like receptors. Immunity 2010; 32: 305-315.
55. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008; 126: 235-242.
56. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. Retrovirology 2010; 7: 54.
57. Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol 2015; 22: 109-115.
58. Moore MD, Hu WS. HIV-1 RNA dimerization: it takes two to tango. AIDS Rev 2009; 11: 91-102.
59. Junt T, Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 2015; 15: 529-544.
60. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007; 81: 8180-8191.
61. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-273.
62. Griesbeck M, Ziegler S, Laffont S, et al. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-a production in women. J Immunol 2015.
63. Berghfer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177: 2088-2096.
64. Laffont S, Rouquie N, Azar P, et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-a production of plasmacytoid dendritic cells from women. J Immunol 2014; 5444-5452.
65. Mir KD, Gasper MA, Sundaravaradan V, Sodora DL. SIV infection in natural hosts: resolution of immune activation during the acute-to-chronic transition phase. Microbes Infect 2011; 13: 14-24.
66. Bosinger SE, Sodora DL, Silvestri G. Generalized immune activation and innate immune responses in simian immunodeficiency virus infection. Curr Opin HIV AIDS 2011; 6: 411-418.
67. Odorizzi PM, Wherry EJ. Immunology. An interferon paradox. Science 2013; 340: 155-156.
68. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340: 207-211.
69. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340: 202-207.
70. Li G, Cheng M, Nunoya J, et al. Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice. PLoS Pathog 2014; 10: e1004291.
71. Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511: 601-605.
72. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
73. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 904-912.
74. Chang JJ, Woods M, Lindsay RJ, et al. Higher expression of several interferonstimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 2013; 208: 830-838.